BETA: Please send your feedback!
Supernus Pharmaceuticals
SUPN:NAS
Pharmaceuticals: Other
$1.37bn
SMALL cap
$26.13
(-0.99%)
-0.24%
since start of 2019
13.02
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 2
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1992
Neurocrine Biosciences, Inc. operates as a product based biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale on January, 1992 and is headquartered in San Diego, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Charles W. Newhall, III, MBA | Chairman | Male |
| Gregory S. Patrick, MBA | CFO, Vice President & Head-Investor Relations | Male |
| Jack A. Khattar, MBA | President, CEO, Secretary & Director | Male |
| Padmanabh P. Bhatt, PhD | Chief Scientific Officer & Senior Vice President | Male |
| Tami Tillotson Martin | Vice President-Regulatory Affairs | Female |
| Stefan K. F. Schwabe, MD, PhD | Chief Medical Officer, EVP-Research & Development | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 2
Neurocrine Biosciences - Competitors and Related Companies
How Neurocrine Biosciences stacks up to its peers in the Biotechnology industry or with competing business segments.
Neurocrine Biosciences
NBIX:NAS
Biotechnology
$8.94bn
MID cap
$97.59
(0.35%)
0.40%
since start of 2019
487.71
Loading…